On-line registration for this event is closed.  Walk-in registration will be accepted. 

Responding to attacks by Congress and prominent academics that government and academic collaboration with pharmaceutical firms creates biases that can undermine the validity of otherwise useful research, the National Institutes of Health recently promulgated regulations that sharply limit outside consulting and other potential conflicts of interest.
      
Taking exception, Harvard Medical School professor Thomas P. Stossel argues in a new article in The New England Journal of Medicine that, on the contrary, collaborative research is often extremely valuable because researchers are capable of keeping scientific goals paramount in their work. Dr. Stossel points out that some of the most useful research in recent decades would have been impossible under the proposed new rules.
      
Following Dr. Stossel's presentation, David Korn, executive director of the leading association of medical schools, and AEI scholar John E. Calfee, who studies the economics of pharmaceutical research and development, will respond.